Swiss National Bank
ADMA icon

Swiss National Bank’s ADMA Biologics ADMA Stock Holding History

Swiss National Bank’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.71M Sell
442,900
-27,700
-6% -$253K ﹤0.01% 1607
2026
Q1 		$4.24M Hold
470,600
– – ﹤0.01% 1455
2025
Q4 		$8.58M Buy
470,600
+7,800
+2% +$131K 0.01% 1046
2025
Q3 		$6.78M Buy
462,800
+8,800
+2% +$151K ﹤0.01% 1167
2025
Q2 		$8.27M Sell
454,000
-4,400
-1% -$89.7K 0.01% 1018
2025
Q1 		$9.09M Hold
458,400
– – 0.01% 945
2024
Q4 		$7.86M Buy
458,400
+28,500
+7% +$536K 0.01% 1063
2024
Q3 		$8.59M Sell
429,900
-3,000
-0.7% -$46.7K 0.01% 1017
2024
Q2 		$4.84M Buy
432,900
+11,800
+3% +$99K ﹤0.01% 1301
2024
Q1 		$2.78M Hold
421,100
– – ﹤0.01% 1648
2023
Q4 		$1.9M Sell
421,100
-18,700
-4% -$69.2K ﹤0.01% 1869
2023
Q3 		$1.57M Buy
439,800
+4,300
+1% +$16.6K ﹤0.01% 1983
2023
Q2 		$1.61M Buy
435,500
+12,500
+3% +$46.3K ﹤0.01% 2032
2023
Q1 		$1.4M Sell
423,000
-49,300
-10% -$170K ﹤0.01% 2052
2022
Q4 		$1.83M Buy
+472,300
New +$1.46M ﹤0.01% 1948

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Swiss National Bank's ADMA Position: Q2 2026 in Review

Swiss National Bank reduced its ADMA Biologics (ADMA) stake by 5.9% in Q2 2026, selling an estimated $253K and leaving 442,900 shares worth $3.71M. The position accounts for ﹤0.01% of the portfolio, ranked #1607.

Swiss National Bank first reported a position in ADMA in Q4 2022 and has held it in 15 quarters since. The position peaked at $9.09M in Q1 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Swiss National Bank held 442,900 shares of ADMA Biologics worth $3.71M as of Q2 2026.
  • Swiss National Bank sold 27,700 ADMA Biologics shares in Q2 2026, an estimated $253K.
  • ADMA Biologics made up ﹤0.01% of Swiss National Bank's portfolio in Q2 2026, its #1607 holding.
  • Swiss National Bank first reported a position in ADMA Biologics in Q4 2022 and has held it in 15 quarters since.
  • Swiss National Bank's ADMA Biologics position peaked at $9.09M in Q1 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.